publication date: May. 12, 2017

Funding Opportunities

DOD Breast Cancer Research Program

FY17 BCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on

As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, J9 Research and Development Directorate manages the Defense Health Program Research, Development, Test, and Evaluation appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs.

Applications submitted to the FY17 BCRP must address one or more of the following overarching challenges:

Prevent breast cancer (primary prevention)

Identify determinants of breast cancer initiation, risk, or susceptibility

Distinguish deadly from non-deadly breast cancers

Conquer the problems of overdiagnosis and overtreatment

Identify what drives breast cancer growth; determine how to stop it

Identify why some breast cancers become metastatic

Determine why/how breast cancer cells lay dormant for years and then re-emerge (recurrence); determine how to prevent recurrence

Revolutionize treatment regimens by replacing them with ones that are more effective, less toxic, and impact survival

Eliminate the mortality associated with metastatic breast cancer 


Breakthrough Award

Pre-applications due June 8 for levels 1 & 2, June 9 for levels 3 & 4; Level 1 & 2 full application due June 15, Level 3 & 4 full application due August 31

Investigators at all academic levels (or equivalent).

Senior postdoctoral fellows who do not meet the eligibility requirements of the Breakthrough Fellowship … Continue reading DOD Breast Cancer Research Program

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.